<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">nogr</journal-id><journal-title-group><journal-title xml:lang="ru">Экспериментальная и клиническая гастроэнтерология</journal-title><trans-title-group xml:lang="en"><trans-title>Experimental and Clinical Gastroenterology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1682-8658</issn><publisher><publisher-name>«Global Media Technologies»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.31146/1682-8658-ecg-212-4-6-11</article-id><article-id custom-type="elpub" pub-id-type="custom">nogr-2356</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ПЕРЕДОВАЯ СТАТЬЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>LEADING ARTICLE</subject></subj-group></article-categories><title-group><article-title>Распространенность избыточной массы тела и ожирения у больных язвенным колитом: исследование случай-контроль</article-title><trans-title-group xml:lang="en"><trans-title>Prevalence of overweight and obesity in patients with ulcerative colitis: a case-control study</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9252-9152</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бикбавова</surname><given-names>Г. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Bikbavova</surname><given-names>G. R.</given-names></name></name-alternatives><email xlink:type="simple">galiya1976@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6581-7017</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ливзан</surname><given-names>М. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Livzan</surname><given-names>M. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4088-240X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лисютенко</surname><given-names>Н. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Lisyutenko</surname><given-names>N. S.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мартыненко</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Martynenko</surname><given-names>O. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1951-5824</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Индутный</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Indutny</surname><given-names>A. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Федеральное государственное бюджетное образовательное учреждение высшего образования «Омский государственный медицинский университет» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Omsk State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Бюджетное учреждение здравоохранения Омской области «Областная клиническая больница»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Regional Clinical Hospital</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>26</day><month>07</month><year>2023</year></pub-date><volume>0</volume><issue>4</issue><fpage>6</fpage><lpage>11</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Бикбавова Г.Р., Ливзан М.А., Лисютенко Н.С., Мартыненко О.В., Индутный А.В., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Бикбавова Г.Р., Ливзан М.А., Лисютенко Н.С., Мартыненко О.В., Индутный А.В.</copyright-holder><copyright-holder xml:lang="en">Bikbavova G.R., Livzan M.A., Lisyutenko N.S., Martynenko O.V., Indutny A.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.nogr.org/jour/article/view/2356">https://www.nogr.org/jour/article/view/2356</self-uri><abstract><p>Заболеваемость и распространенность воспалительных заболеваний кишечника (ВЗК) растёт параллельно с пандемией ожирения. География распределения ожирения и ВЗК по планете имеют общие черты. В последние годы появляется информация об эпидемиологическом взаимодействии предрасполагающих факторов к ожирению и язвенному колиту (ЯК). Цель исследования: оценка распространенности избыточной массы тела и ожирения у больных ЯК региона Западная Сибирь. Материалы и методы: проведено исследование типа «случай-контроль» 165 язвенным колитом 56 здоровых добровольцев сопоставимых по полу и по возрасту. Индекс массы тела (ИМТ) рассчитывали по формуле: масса (кг)/вес (м2). Результаты: лишь у 7,9% больных ЯК ИМТ соответствовал недостатку массы тела, у 48% ИМТ в пределах нормальных показателей, в 43% случаев ИМТ соответствовал избыточному весу и ожирению. При этом средние значения и медиана ИМТ у больных ЯК при остром и вариантах хронического течения заболевания близки к верхним показателям нормальных значений. Гендерных различий ИМТ в сравнении контрольной группы нет. ИМТ пациентов с тяжелой атакой значимо меньше ИМТ пациентов с атакой средней степени тяжести. Гормональная зависимость и резистентность, применение ГИБП не оказывали существенного влияния на ИМТ больных ЯК. У пациентов с ЯК при сравнении с контрольной группой значимо больше встречается больных сахарным диабетом 2 типа. Однако значимой зависимости между степенью тяжести текущей атаки среди больных ЯК и наличием у них сахарного диабета 2 типа выявлено не было. При сравнении группы больных ЯК с контрольной группой значимых отличий по частоте встречаемости НАЖБП, желчнокаменной болезни, ишемической болезнью сердца, артериальной гипертензией выявлено не было, при этом у больных с непрерывно рецидивирующим течением ЯК значимо чаще встречается поражение печени, характерные для НАЖБП.</p></abstract><trans-abstract xml:lang="en"><p>The incidence and prevalence of inflammatory bowel diseases (IBD) is growing in parallel with the obesity pandemic. The geography of the distribution of obesity and IBD on the planet have common features. In recent years, there has been information about the epidemiological interaction of predisposing factors to obesity and ulcerative colitis (UC). The aim of the study was to assess the prevalence of overweight and obesity in patients with UC in the Western Siberia region. Materials and methods: a case-control study of 165 ulcerative colitis was conducted in 56 healthy volunteers of comparable gender and age. Body mass index (BMI) was calculated using the formula: weight (kg)/weight (m2). Results: only in 7.9% of patients with UC BMI corresponded to a lack of body weight, in 48% BMI within normal parameters, in 43% of cases BMI corresponded to overweight and obesity. At the same time, the average values and median BMI in UC patients with acute and chronic course of the disease are close to the upper values of normal values. There are no gender differences in BMI compared to the control group. The BMI of patients with severe attack is significantly less than the BMI of patients with moderate attack. Hormonal dependence and resistance, the use of GIBP did not have a significant effect on the BMI of UC patients. In patients with UC, when compared with the control group, there are significantly more patients with type 2 diabetes mellitus. However, there was no significant relationship between the severity of the current attack among UC patients and the presence of type 2 diabetes mellitus in them. When comparing the group of patients with UC with the control group, there were no significant differences in the frequency of occurrence of NAFLD, cholelithiasis, coronary heart disease, arterial hypertension, while in patients with continuously recurrent UC, liver damage characteristic of NAFLD is significantly more common.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>язвенный колит</kwd><kwd>индекс массы тела</kwd><kwd>ожирение</kwd></kwd-group><kwd-group xml:lang="en"><kwd>ulcerative colitis</kwd><kwd>body mass index</kwd><kwd>obesity</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Ramos G., Papadakis K. Mechanisms of Disease: Inflammatory Bowel Diseases. Mayo Clin. Proc. 2019 Jan;94(1):155-165. doi: 10.1016/j.mayocp.2018.09.013.</mixed-citation><mixed-citation xml:lang="en">Ramos G., Papadakis K. Mechanisms of Disease: Inflammatory Bowel Diseases. Mayo Clin. Proc. 2019 Jan;94(1):155-165. doi: 10.1016/j.mayocp.2018.09.013.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">GBD2017 Inflammatory Bowel Disease Collaborators. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020 Jan;5(1):17-30. doi: 10.1016/S2468-1253(19)30333-4.</mixed-citation><mixed-citation xml:lang="en">GBD2017 Inflammatory Bowel Disease Collaborators. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020 Jan;5(1):17-30. doi: 10.1016/S2468-1253(19)30333-4.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Kaplan G. G., Ng S. C. Understanding and preventing the global increase of inflammatory bowel disease. Gastroenterology. 2017 Feb;152(2):313-321.e2. doi: 10.1053/j.gastro.2016.10.020.</mixed-citation><mixed-citation xml:lang="en">Kaplan G. G., Ng S. C. Understanding and preventing the global increase of inflammatory bowel disease. Gastroenterology. 2017 Feb;152(2):313-321.e2. doi: 10.1053/j.gastro.2016.10.020.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Maev I.V., Shelygin Yu.A., Skalinskaya M. I. et al. The Pathomorphosis of Inflammatory Bowel Diseases. Annals of the Russian Academy of Medical Sciences. 2020;75(1):27-35. doi: 10.15690/vramn1219.@@ Маев И. В., Шелыгин Ю. А., Скалинская М. И. и соавт. Патоморфоз воспалительных заболеваний кишечника. Вестник РАМН. 2020;75(1):27-35. doi: 10.15690/vramn1219.</mixed-citation><mixed-citation xml:lang="en">Maev I.V., Shelygin Yu.A., Skalinskaya M. I. et al. The Pathomorphosis of Inflammatory Bowel Diseases. Annals of the Russian Academy of Medical Sciences. 2020;75(1):27-35. doi: 10.15690/vramn1219.@@ Маев И. В., Шелыгин Ю. А., Скалинская М. И. и соавт. Патоморфоз воспалительных заболеваний кишечника. Вестник РАМН. 2020;75(1):27-35. doi: 10.15690/vramn1219.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Bernstein C. N., Rawsthorne P., Cheang M. et al. A population-based case control study of potential risk factors for IBD. Am. J. Gastroenterol. 2006 May;101(5):993-1002. doi: 10.1111/j.1572-0241.2006.00381.x.</mixed-citation><mixed-citation xml:lang="en">Bernstein C. N., Rawsthorne P., Cheang M. et al. A population-based case control study of potential risk factors for IBD. Am. J. Gastroenterol. 2006 May;101(5):993-1002. doi: 10.1111/j.1572-0241.2006.00381.x.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Bischoff S.C., Barazzoni R., Busetto L., Campmans-Kuijpers M. et al. European guideline on obesity care in patients with gastrointestinal and liver diseases - Joint European Society for Clinical Nutrition and Metabolism / United European Gastroenterology guideline. United European Gastroenterol J. 2022 Sep;10(7):663-720. doi: 10.1002/ueg2.12280.</mixed-citation><mixed-citation xml:lang="en">Bischoff S.C., Barazzoni R., Busetto L., Campmans-Kuijpers M. et al. European guideline on obesity care in patients with gastrointestinal and liver diseases - Joint European Society for Clinical Nutrition and Metabolism / United European Gastroenterology guideline. United European Gastroenterol J. 2022 Sep;10(7):663-720. doi: 10.1002/ueg2.12280.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Johnson AM, Loftus EV. Obesity in inflammatory bowel disease: A review of its role in the pathogenesis, natural history, and treatment of IBD. Saudi J Gastroenterol. 2021 Jul-Aug;27(4):183-190. doi: 10.4103/sjg.sjg_30_21.</mixed-citation><mixed-citation xml:lang="en">Johnson AM, Loftus EV. Obesity in inflammatory bowel disease: A review of its role in the pathogenesis, natural history, and treatment of IBD. Saudi J Gastroenterol. 2021 Jul-Aug;27(4):183-190. doi: 10.4103/sjg.sjg_30_21.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Garvey W. T., Garber A. J., Mechanick J. I. et al. On behalf of the AACE obesity scientific C. American association of clinical endocrinologists and american college of endocrinology position statement on the 2014 advanced framework for a new diagnosis of obesity as a chronic disease. Endocr Pract. 2014 Sep;20(9):977-89. doi: 10.4158/EP14280.PS.</mixed-citation><mixed-citation xml:lang="en">Garvey W. T., Garber A. J., Mechanick J. I. et al. On behalf of the AACE obesity scientific C. American association of clinical endocrinologists and american college of endocrinology position statement on the 2014 advanced framework for a new diagnosis of obesity as a chronic disease. Endocr Pract. 2014 Sep;20(9):977-89. doi: 10.4158/EP14280.PS.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Fink C., Iordanes K., Bakirtzi K. et al. Adipose tissue and inflammatory bowel disease pathogenesis. Inflamm Bowel Dis. 2012 Aug;18(8):1550-7. doi: 10.1002/ibd.22893.</mixed-citation><mixed-citation xml:lang="en">Fink C., Iordanes K., Bakirtzi K. et al. Adipose tissue and inflammatory bowel disease pathogenesis. Inflamm Bowel Dis. 2012 Aug;18(8):1550-7. doi: 10.1002/ibd.22893.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Versini M., Jeandel P. Y., Rosenthal E. et al. Obesity in autoimmune diseases: Not a passive bystander. Autoimmunity Rev. 2014 Sep;13(9):981-1000. doi: 10.1016/j.autrev.2014.07.001.</mixed-citation><mixed-citation xml:lang="en">Versini M., Jeandel P. Y., Rosenthal E. et al. Obesity in autoimmune diseases: Not a passive bystander. Autoimmunity Rev. 2014 Sep;13(9):981-1000. doi: 10.1016/j.autrev.2014.07.001.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Kinlen D., Cody D., O’Shea D.Complications of obesity. QJM. 2018 Jul 1;111(7):437-443. doi: 10.1093/qjmed/hcx152.</mixed-citation><mixed-citation xml:lang="en">Kinlen D., Cody D., O’Shea D.Complications of obesity. QJM. 2018 Jul 1;111(7):437-443. doi: 10.1093/qjmed/hcx152.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Livzan M. A., Krolevets T. S., Lapteva I. V., Cherkashchenko N. A. Non-alcoholic fatty liver disease in persons with abdominal type of obesity. Evidence-based Gastroenterology. 2014, No.4, pp. 8-14. doi: 10.17116/dokgastro2014348-14.@@ Ливзан М. А., Кролевец Т. С., Лаптева И. В., Черкащенко Н. А. Неалкогольная жировая болезнь печени у лиц с абдоминальным типом ожирения. Доказательная гастроэнтерология. -2014, -№.4, -С. 8-14. doi: 10.17116/dokgastro2014348-14.</mixed-citation><mixed-citation xml:lang="en">Livzan M. A., Krolevets T. S., Lapteva I. V., Cherkashchenko N. A. Non-alcoholic fatty liver disease in persons with abdominal type of obesity. Evidence-based Gastroenterology. 2014, No.4, pp. 8-14. doi: 10.17116/dokgastro2014348-14.@@ Ливзан М. А., Кролевец Т. С., Лаптева И. В., Черкащенко Н. А. Неалкогольная жировая болезнь печени у лиц с абдоминальным типом ожирения. Доказательная гастроэнтерология. -2014, -№.4, -С. 8-14. doi: 10.17116/dokgastro2014348-14.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Yorulmaz, E., Adali, G., Yorulmaz, H. et al. Metabolic syndrome frequency in inflammatory bowel diseases. Saudi J. Gastroenterol. 2011 Nov-Dec;17(6):376-82. doi: 10.4103/1319-3767.87177.</mixed-citation><mixed-citation xml:lang="en">Yorulmaz, E., Adali, G., Yorulmaz, H. et al. Metabolic syndrome frequency in inflammatory bowel diseases. Saudi J. Gastroenterol. 2011 Nov-Dec;17(6):376-82. doi: 10.4103/1319-3767.87177.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Zamani, M., Alizadeh-Tabari S., Singh S. et al. Meta-analysis: Prevalence of, and risk factors for, non-alcoholic fatty liver disease in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 2022 Apr;55(8):894-907. doi: 10.1111/apt.16879.</mixed-citation><mixed-citation xml:lang="en">Zamani, M., Alizadeh-Tabari S., Singh S. et al. Meta-analysis: Prevalence of, and risk factors for, non-alcoholic fatty liver disease in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 2022 Apr;55(8):894-907. doi: 10.1111/apt.16879.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Noorian S., Jeon Y., Nguyen M. T. et al. The Impact of NAFLD on Hospitalization Outcomes in Patients With Inflammatory Bowel Diseases: Nationwide Analysis. Inflamm. Bowel Dis. 2022 Jun 3;28(6):878-887. doi: 10.1093/ibd/izab199.</mixed-citation><mixed-citation xml:lang="en">Noorian S., Jeon Y., Nguyen M. T. et al. The Impact of NAFLD on Hospitalization Outcomes in Patients With Inflammatory Bowel Diseases: Nationwide Analysis. Inflamm. Bowel Dis. 2022 Jun 3;28(6):878-887. doi: 10.1093/ibd/izab199.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Lees C.W., Barrett J. C., Parkes M., Satsangi J. New IBD genetics: Common pathways with other diseases. Gut 2011, 60, 1739-1753. doi: 10.1136/gut.2009.199679</mixed-citation><mixed-citation xml:lang="en">Lees C.W., Barrett J. C., Parkes M., Satsangi J. New IBD genetics: Common pathways with other diseases. Gut 2011, 60, 1739-1753. doi: 10.1136/gut.2009.199679</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Sang MM, Sun ZL, Wu TZ. Inflammatory bowel disease and diabetes: Is there a link between them? World J Diabetes. 2022 Feb 15;13(2):126-128. doi: 10.4239/wjd.v13.i2.126.</mixed-citation><mixed-citation xml:lang="en">Sang MM, Sun ZL, Wu TZ. Inflammatory bowel disease and diabetes: Is there a link between them? World J Diabetes. 2022 Feb 15;13(2):126-128. doi: 10.4239/wjd.v13.i2.126.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Rodriguez-Duque J.C., Calleja J. L., Iruzubieta P. et al. Increased risk of MAFLD and Liver Fibrosis in Inflammatory Bowel Disease Independent of Classic Metabolic Risk Factors. Clin. Gastroenterol. Hepatol. 2023 Feb;21(2):406-414.e7. doi: 10.1016/j.cgh.2022.01.039.</mixed-citation><mixed-citation xml:lang="en">Rodriguez-Duque J.C., Calleja J. L., Iruzubieta P. et al. Increased risk of MAFLD and Liver Fibrosis in Inflammatory Bowel Disease Independent of Classic Metabolic Risk Factors. Clin. Gastroenterol. Hepatol. 2023 Feb;21(2):406-414.e7. doi: 10.1016/j.cgh.2022.01.039.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Clinical recommendations “Ulcerative colitis”, 2020, developer of clinical recommendations Russian Gastroenterological Association; Association of Coloproctologists of Russia. Approved by the Scientific and Practical Council of the Ministry of Health of the Russian Federation.@@ Клинические рекомендации «Язвенный колит», 2020, разработчик клинических рекомендаций Российская гастроэнтерологическая ассоциация; Ассоциация колопроктологов России. Одобрено Научно-практическим Советом Миннздрава РФ.</mixed-citation><mixed-citation xml:lang="en">Clinical recommendations “Ulcerative colitis”, 2020, developer of clinical recommendations Russian Gastroenterological Association; Association of Coloproctologists of Russia. Approved by the Scientific and Practical Council of the Ministry of Health of the Russian Federation.@@ Клинические рекомендации «Язвенный колит», 2020, разработчик клинических рекомендаций Российская гастроэнтерологическая ассоциация; Ассоциация колопроктологов России. Одобрено Научно-практическим Советом Миннздрава РФ.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
